Catalyst Pharmaceuticals logo
Catalyst Pharmaceuticals CPRX
$ 24.91 2.51%

Quarterly report 2025-Q3
added 11-05-2025

report update icon

Catalyst Pharmaceuticals Net Debt 2011-2026 | CPRX

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Catalyst Pharmaceuticals

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-514 M -134 M -295 M -167 M - -88.6 M -16.6 M -57.5 M -13.9 M -28.2 M -9.1 M -2.22 M -1.41 M -6.03 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-1.41 M -514 M -103 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
-60.6 M - 1052.0 % $ 415 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
94.7 M $ 18.38 -0.68 % $ 2.7 B usaUSA
Amgen Amgen
AMGN
44.7 B $ 344.65 0.81 % $ 185 B usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
-115 M $ 71.99 3.84 % $ 9.63 B usaUSA
Biogen Biogen
BIIB
4.01 B $ 178.18 -0.95 % $ 25.9 B usaUSA
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Aytu BioScience Aytu BioScience
AYTU
-19.9 M $ 2.65 1.92 % $ 16.6 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Adagene Adagene
ADAG
-71 M $ 2.96 7.64 % $ 167 M chinaChina
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Burford Capital Limited Burford Capital Limited
BUR
-135 M $ 9.83 1.44 % $ 1.59 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-3.5 M $ 4.16 3.74 % $ 9.05 B israelIsrael
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
-34.7 M $ 3.18 0.32 % $ 7.65 B australiaAustralia
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
-5.05 M $ 1.86 1.1 % $ 167 M israelIsrael
Aptose Biosciences Aptose Biosciences
APTO
-5.53 M - -45.71 % $ 1.2 M canadaCanada
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
Celldex Therapeutics Celldex Therapeutics
CLDX
-24.5 M $ 24.86 1.06 % $ 1.6 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
-206 M $ 3.87 2.22 % $ 116 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
-21.3 M $ 1.41 - $ 264 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-239 M - -0.23 % $ 916 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-195 M $ 224.87 -0.54 % $ 5 B danmarkDanmark
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-12 M - -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-56.5 M - - $ 10.1 M usaUSA
Aravive Aravive
ARAV
-49.6 M - -13.39 % $ 1.45 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
-121 M $ 40.98 2.78 % $ 4.23 B usaUSA
BioNTech SE BioNTech SE
BNTX
-973 M $ 110.01 -3.29 % $ 27.2 B germanyGermany
Athira Pharma Athira Pharma
ATHA
-47.2 M - - $ 269 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-187 M $ 1.39 1.5 % $ 355 M britainBritain
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
AVROBIO AVROBIO
AVRO
-76.6 M - 1083.1 % $ 745 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
-49.9 M $ 1.73 -1.43 % $ 82.4 M usaUSA
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
-119 M - -15.15 % $ 60.3 M britainBritain
DBV Technologies S.A. DBV Technologies S.A.
DBVT
-25.5 M $ 21.75 0.65 % $ 2.11 B franceFrance
Brickell Biotech Brickell Biotech
BBI
-29.7 M - -5.38 % $ 6.06 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
2.28 B $ 14.25 4.13 % $ 4.4 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
-1.04 M - 1.93 % $ 17.4 M usaUSA
Atreca Atreca
BCEL
33.1 M - -11.76 % $ 5.79 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
-2.08 M - 2.71 % $ 14 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
211 M $ 6.72 2.05 % $ 1.39 B usaUSA